SCHEMBL5539503

SCHEMBL5539503

[CH2]c1ccccc1NCc1ccc(Cl)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
KDM4E B2RXH2 3/20 0.49
GAA P10253 2/20 0.46
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
ALDH1A1 P00352 2/20 0.44
ALOX12 P18054 2/20 0.44
THRB P10828 1/20 0.44
EGFR P00533 2/20 0.43
CHRM2 P08172 1/20 0.43
HSD17B10 Q99714 1/20 0.43
IGF1R P08069 1/20 0.43
FLT4 P35916 1/20 0.43
KDR P35968 1/20 0.43
RAB9A P51151 2/20 0.42
APP P05067 1/20 0.42
HPGD P15428 1/20 0.42
NPC1 O15118 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12263035 0.86 MAPT (0.64) MAPTL3MBTL1KDM4EGAAKMT2A
SCHEMBL5538885 0.84 HSD17B10 (0.59) MAPTL3MBTL1KDM4EKMT2AMEN1
SCHEMBL5535113 0.84 ACLY (0.48) MAPTL3MBTL1KDM4EGAAKMT2A
SCHEMBL5546124 0.81 KDM4E (0.44) MAPTL3MBTL1KDM4EGAAKMT2A
SCHEMBL5544675 0.81 MAPT (0.44) MAPTL3MBTL1KDM4EGAAKMT2A
SCHEMBL5542578 0.81 HTT (0.52) MAPTL3MBTL1KDM4EGAAKMT2A
SCHEMBL5534733 0.81 KCNH3 (0.45) MAPTKDM4EKMT2AMEN1ALDH1A1
SCHEMBL11513298 0.81 MAPT (0.58) MAPTL3MBTL1KDM4EGAAKMT2A
SCHEMBL5539354 0.81 CHRM2 (0.51) MAPTKMT2ACHRM2IGF1RAPP
SCHEMBL5544370 0.81 SSTR3 (0.51) MAPTL3MBTL1KDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885L3MBTL1 1931/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.